AML Treatment Sees Major Advancements with 12 New Drug Approvals

Acute Myeloid Leukemia (AML) treatment has seen remarkable progress over the past 18 years, with 12 drug approvals including IDH and FLT3 inhibitors, and the transformative venetoclax and azacitidine combination therapy. This surge of innovation contrasts sharply with the decades of stagnation in AM

8 months ago

Science & Energy

Biotech Leaders Clash on Partnership Strategy for Drug Development

A debate among biotech leaders revealed sharply contrasting views on the role of partnerships in drug development. Desh, CEO of Protagonist Therapeutics, strongly advocates for collaborations, citing their importance for external validation, financial resources, and leveraging the extensive experien

8 months ago